Achillion Pharmaceuticals (NASDAQ:ACHN) Analyst Rating Consensus

Achillion Pharmaceuticals (NASDAQ:ACHN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.33 by 6 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.

Other Equity analysts have also commented on the company shares. Leerink Swann maintains their rating on the shares of Achillion Pharmaceuticals (NASDAQ:ACHN). The current rating of the shares is Market Perform. Equity Analysts at the Firm raises the price target to $9 per share from $7 per share. The rating by the firm was issued on May 4, 2016.

Achillion Pharmaceuticals (NASDAQ:ACHN): The mean estimate for the short term price target for Achillion Pharmaceuticals (NASDAQ:ACHN) stands at $9.5 according to 6 Analysts. The higher price target estimate for the stock has been calculated at $16 while the lower price target estimate is at $7.

Achillion Pharmaceuticals (NASDAQ:ACHN) witnessed a decline in the market cap on Tuesday as its shares dropped 2.43% or 0.21 points. After the session commenced at $8.67, the stock reached the higher end at $8.67 while it hit a low of $8.35. With the volume soaring to 1,014,042 shares, the last trade was called at $8.42. The company has a 52-week high of $10.95. The company has a market cap of $1,151 million and there are 136,640,020 shares in outstanding. The 52-week low of the share price is $5.57.

Achillion Pharmaceuticals, Inc. is up 13.17% in the last 3-month period. Year-to-Date the stock performance stands at -21.96%.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.